Som følge af en reduktion af den systemiske vaskulære modstand opnås der en klinisk signifikant reduktion af blodtrykket, når Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne gives til hypertensive patienter.
Administration of Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]in hypertensive patients causes a clinically significant reduction in blood pressure as a result of a reduction in systemic vascular resistance.